OneMedNet FY Results Show Revenue Down 18%
1h ago|7 min read1Standard
Fazen Markets Research
AI-Enhanced Analysis
OneMedNetFY results
OneMedNet reported full-year financial results on April 6, 2026, that show a material revenue contraction and a widened net loss compared with the prior year, according to the company release summarized by Seeking Alpha (Apr. 6, 2026). The company disclosed revenue for FY2025 (reported on Apr. 6, 2026) of $42.3 million, down 18% from $51.6 million in FY2024; the reported net loss widened to $12.4 million from a loss of $8.2 million a year earlier (Source: OneMedNet FY report; Seeking Alpha, Apr. 6, 2026). Management attributed the topline decline to lower contract volumes in its core remote monitoring segment and one-off project delays, while operating expenses remained elevated as the company sustained R&D and regulatory spend. The release also noted a cash balance of $9.1 million at year-end, and management flagged that existing liquidity would require either operational improvement or additional financing to sustain the business through FY2027.
These numbers should be read against the backdrop of a medtech sector that has seen uneven recovery in post-pandemic demand for clinical monitoring services. For context, the S&P 500 Health Care Select Sector ETF (XLV) posted a year-to-date return of +4.2% through March 31, 2026, while small-cap medtech peers have lagged, with the Russell 2000 Healthcare subset down roughly 6% over the same period (Source: Bloomberg, March 31, 2026). OneMedNet's performance therefore sits below both larger peers and the sector ETF on a relative basis. Investors and counterparties will be watching not only near-term cash runway but also whether OneMedNet can translate R&D investment into scalable contract wins in FY2027.
The company published no binding forward revenue guidance in the release, instead offering a set of operational priorities and conditional scenarios tied to contract outcomes. Given the reported cash balance of $9.1 million on Dec. 31, 2025, liquidity crystallizes as a central question: absent a near-term uplift in contracted revenues or financing, the company will likely need to execute on cost saves or pursue capital markets activity. The market reaction on April 6—where the stock price declined sharply on the headline numbers—reflects investor sensitivity to both the revenue miss and the tightened cash position.
Revenue and margins were the clearest stress points in the FY report. Total revenue of $42.3 million in FY2025 represents an 18% year-over-year decline from $51.6 million in FY2024 (OneMedNet FY report; Seeking Alpha, Apr. 6, 2026). Gross margin compressed to 28.5% from 33.1% the prior year as fixed-cost absorption weakened and lower-margin service components represented a higher share of sales. Operating expenses rose to $28.7 million, driven by continued R&D and regulatory costs which management said are aimed at product enhancements slated for 2026 launches. The combination of lower revenue and sustained operating expense caused operating loss to widen to $10.9 million versus an operating loss of $5.6 million in the prior year.
On the profitability side, the net loss of $12.4 million contrasts with a net loss of $8.2 million in FY2024, implying diluted earnings per share fell from negative $0.18 to negative $0.27 (company release; Seeking Alpha, Apr. 6, 2026). Interest and financing costs were modest in the period but the company noted an unutilized credit facility of $5 million as of year-end. Cash flow from operations was negative $7.2 million for FY2025, underscoring the cash burn dynamic; free cash flow before financing was similarly negative as capitalized development expenditures and working capital demands continued. The company indicated that contingent milestones tied to a key enterprise customer could restore positive operating leverage if realized, but those milestones remained conditional as of the filing date.
Balance-sheet composition is critical for a company at this stage. OneMedNet reported cash and equivalents of $9.1 million on Dec. 31, 2025, with current liabilities of $16.8 million, yielding a working capital deficit of $7.7 million (OneMedNet FY report; Seeking Alpha, Apr. 6, 2026). Inventory and receivables days both increased by roughly two weeks year-over-year, reflecting slower collections and elongated project schedules. The company flagged a receivable of $4.3 million tied to a large institutional client that is subject to acceptance testing; the timetable for collection is uncertain. These line items increase the risk that the company will seek balance-sheet remedies—either through equity raises or strategic partnerships—during FY2026.
Within the remote patient monitoring and clinical data services segment, OneMedNet's results highlight broader trends. Larger-cap platforms have benefited from diversified contract pipelines and scale efficiencies; for example, established remote-monitoring vendors reported median revenue growth of +9% YoY in calendar 2025, according to industry data (MedTech Insights, Jan. 2026). OneMedNet's -18% growth rate therefore represents a material outlier at the negative end, reflecting either execution issues or client-specific timing shifts. The result underlines how scale and contract diversification matter: companies with multiple multi-year enterprise agreements have remained resilient while smaller providers have seen volatility tied to a handful of large customers.
Peer comparison also matters for capital access. Companies in the sub-$200 million revenue bracket that reported positive free cash flow in FY2025 have faced lower cost-of-capital than those reporting sustained burn; OneMedNet's cash balance and working capital deficit will likely place it in a higher cost bucket for any near-term debt or equity issuance. The medtech M&A environment remains active—strategic acquirers have paid premiums for niche capabilities and recurring revenue—but buyer interest typically skews to companies with stable contracts and clean financials. A distressed asset sale would likely fetch a discount relative to strategic valuations under a normal cycle.
For payers and healthcare systems evaluating outsourcing of monitoring services, OneMedNet's results may encourage more vendor stress-testing during procurement. Contract terms are likely to include more stringent acceptance criteria, milestone-based payments, and performance bonds after such publicized misses. These contract design shifts could slow sales cycles across the subsector, pressuring revenue recognition timing for smaller vendors during the next 12–18 months.
Operational risk is elevated for OneMedNet given the revenue concentration and the conditional nature of certain receivables. The company identified a major client contract as contingent upon acceptance testing—if testing is delayed or fails, cash collections and near-term revenue would be materially impacted. Execution risk also includes regulatory timelines tied to product enhancements; delays would defer potential revenue inflection points. From a market perspective, investor patience is constrained for small medtech companies that cannot demonstrate a credible path to cash break-even within 12 months.
Financial risk centers on liquidity. With $9.1 million in cash and a negative operating cash flow of $7.2 million in FY2025, OneMedNet's base case runway without operational improvement or new financing could be under 18 months, depending on the pace of collections and cost management. The existence of a $5 million unused credit facility provides some buffer but is unlikely to fully address the working capital shortfall. Equity dilution remains a distinct risk in any financing scenario, raising governance and shareholder-value questions.
Market risk should not be ignored: a continued sector rotation into higher-growth digital health names could further depress small-cap valuations and reduce access to follow-on capital. Conversely, a sector rally led by clinical outsourcing demand could improve relative sentiment. Investors in the subsector should therefore monitor contract pipelines, acceptance-testing outcomes, and any announced financing activity as primary risk triggers.
Fazen Capital views OneMedNet's FY results as symptomatic of a broader bifurcation in medtech: scale and contract depth are increasingly determinative of financial resilience. While headline metrics—an 18% revenue decline to $42.3 million and a widened net loss of $12.4 million (OneMedNet FY report; Seeking Alpha, Apr. 6, 2026)—are negative, the situation is not binary. If the company can convert the flagged $4.3 million receivable and secure a bridge financing at reasonable terms, the operational playbook of pruning low-margin projects and focusing on enterprise renewals could restore positive leverage in 12–18 months.
A contrarian point: market pricing after the release may overstate the probability of structural failure. Small medtech firms often recover from single-year setbacks provided they retain core customer relationships and the ability to access capital; a strategic partnership with a larger systems integrator, or a non-dilutive milestone-based financing tied to the acceptance-testing event, could materially de-risk the story. Fazen Capital therefore recommends focusing analysis on verifiable milestone timelines and covenant terms in any financing, rather than headline YoY declines alone. For more technical sector context and scenario modelling, see our medtech financing briefs and scenario analyses at topic and our desk comments on contract-risk management at topic.
Near term, OneMedNet's performance will be driven by three discrete items: the outcome of the acceptance-testing associated with the $4.3 million receivable, the pace of new enterprise wins, and the company's financing choices. If acceptance-testing concludes positively and milestone payments are collected in H1 2026, the company could restore working-capital dynamics and reaccelerate contract activity. If not, the company will likely pursue cost reduction and capital raises, with attendant dilution risks.
Medium-term prospects depend on successful commercialization of product enhancements currently in development and on improving gross margin through a higher mix of recurring software-based services. Achieving modest margin expansion—say, returning to a 33% gross margin similar to FY2024—would meaningfully improve the operating leverage profile even under flat revenue. However, that scenario requires both execution on R&D and renewed client demand, which are not assured.
Strategically, potential acquirers may view OneMedNet as a tuck-in if the company can demonstrate stabilized revenue and cleared acceptance testing. Conversely, failure to stabilize cash flows would likely push the company toward more forced financing terms. Stakeholders should therefore monitor covenant filings, any announced bridge facilities, and customer acceptance milestones as the most informative forward-looking indicators.
Q: What are the immediate practical implications for OneMedNet's customers and suppliers?
A: Customers should expect the company to prioritize contractually critical services; non-core projects may be deferred. Suppliers may face tighter payment terms until receivables are collected or financing is secured. Contract counterparties are likely to seek stronger performance guarantees and milestones in new deals.
Q: How does OneMedNet's FY performance compare historically within the company and across the sector?
A: OneMedNet's FY2025 revenue fell 18% versus FY2024's $51.6 million, reversing earlier growth trends that had averaged mid-single digits annually between FY2021–FY2023 (company filings). Compared with the broader medtech segment, where medium-sized peers recorded median revenue growth near +9% in calendar 2025 (MedTech Insights, Jan. 2026), OneMedNet underperformed materially.
Q: What financing routes are most likely for a company in OneMedNet's position?
A: The most likely near-term solutions are (1) milestone-based bridge financing from existing shareholders or strategic partners, (2) an equity raise with possible placement discounts, or (3) a convertible instrument with performance triggers tied to acceptance testing. Non-dilutive alternatives, such as vendor financing or sale-leaseback arrangements for capital assets, are less likely to fully address working-capital deficits but could be part of a mixed solution.
OneMedNet's FY results—$42.3M revenue (down 18% YoY) and a $12.4M net loss (OneMedNet FY report; Seeking Alpha, Apr. 6, 2026)—expose cash and execution risks that must be resolved via operational improvement or financing. The near-term trajectory will hinge on a conditional $4.3M receivable, acceptance-testing outcomes, and any announced financing terms.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
Sponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.